Alzamend Neuro, Inc. (ALZN) [Rocket]

In millions, except per share items	Apr-30-23	Jan-31-23	Oct-31-22	Jul-31-22	Apr-30-22	Jan-31-22	Oct-31-21	Jul-31-21
	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q
Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]	1.7	2.5	1.6	1.7	2.2	1.7	1.8	1.4
General and administrative	1.7	2.5	1.6	1.7	2.2	1.7	1.8	1.4
Research and development	1.6	2.9	1.5	1.4	1.7	0.9	1.8	0.9
EBITDA [+]	-3.3	-5.4	-3.1	-3.0	-3.9
EBITDA growth	-14.7%	111.9%	-13.5%	31.3%	217.2%	129.2%	176.1%	74.9%
Depreciation and amortization	0.0	0.0	0.0	0.0	0.0
EBIT [+]	-3.3	-5.4	-3.1	-3.0	-3.9	-2.6	-3.6	-2.3
EBIT growth	-14.7%	112.1%	-13.3%	31.6%	217.4%	129.2%	176.1%	74.9%
Interest expense	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest expense	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other income (expense), net					0.0
Pre-tax income	-3.3	-5.4	-3.1	-3.0	-3.9	-2.6	-3.6	-2.3
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-3.3	-5.4	-3.1	-3.0	-3.9	-2.6	-3.6	-2.3

Basic EPS [+]	($0.03)	($0.06)	($0.03)	($0.03)	($0.04)	($0.03)	($0.04)	($0.03)
Growth	-22.0%	102.0%	-17.2%	13.6%	151.0%	36.6%	105.6%	50.5%
Diluted EPS [+]	($0.03)	($0.06)	($0.03)	($0.03)	($0.04)	($0.03)	($0.04)	($0.03)
Growth	-22.0%	102.0%	-17.2%	13.6%	151.0%	36.6%	105.6%	50.5%

Shares outstanding (basic) [+]	97.5	98.3	97.5	97.5	89.1	94.2	93.5	84.6
Growth	9.5%	4.4%	4.3%	15.2%	22.6%	68.3%	29.3%	17.1%
Shares outstanding (diluted) [+]	97.5	98.3	97.5	97.5	89.1	94.2	93.5	84.6
Growth	9.5%	4.4%	4.3%	15.2%	22.6%	68.3%	29.3%	17.1%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.